Global Pruritus Therapeutics Market – Analysis and Demand with Forecast Overview to 2029 - by PMI
20 janv. 2021 11h05 HE
|
PMI
Covina CA, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Growing worldwide prevalence of atopic dermatitis, allergic contact dermatitis, and urticaria is expected to drive market growth during the forecast...
Trevi Therapeutics Announces Election of Dominick C. Colangelo to Board of Directors
30 juin 2020 16h45 HE
|
Trevi Therapeutics
NEW HAVEN, Conn., June 30, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER...
Trevi Therapeutics Announces Third Quarter 2019 Financial Results and Recent Business Developments
14 nov. 2019 16h05 HE
|
Trevi Therapeutics
Advancement of Nalbuphine ER in Clinical Development for Three Indications Cash Position of $63.5 Million Expected to Fund Operations Through At Least Q1 2021 NEW HAVEN, Conn., Nov. 14, 2019 ...
Trevi Therapeutics to Present at Stifel Healthcare Conference
13 nov. 2019 17h01 HE
|
Trevi Therapeutics
NEW HAVEN, Conn., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine...
Trevi Therapeutics to Participate in Panel Discussion at BTIG Pain / Pruritus Management Forum
05 sept. 2019 16h05 HE
|
Trevi Therapeutics
NEW HAVEN, Conn., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of...
Trevi Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference
18 juin 2019 16h05 HE
|
Trevi Therapeutics
NEW HAVEN, Conn., June 18, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine...
Trevi Therapeutics Announces First Quarter 2019 Financial Results and Recent Business Developments
13 juin 2019 16h09 HE
|
Trevi Therapeutics
Raised $70 Million in Gross Proceeds from Initial Public Offering and Concurrent Private Placement Initiated Phase 2 Clinical Trial for Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis...
Trevi Therapeutics Announces Pricing of Initial Public Offering
07 mai 2019 13h22 HE
|
Trevi Therapeutics
NEW HAVEN, Conn., May 07, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to...